A technology developed at the University of Birmingham, U.K., has been spun off as a potential treatment for ocular surface diseases. The platform technology from startup Healome Therapeutics Ltd. was developed by a team of material scientists at the University’s Healthcare Technologies Institute (HTI) that translates health technology concepts to products for clinical trials. Read More
Cambridge Innovation Capital (CIC) has closed its oversubscribed Fund II at £225 million (US$287 million) and is moving from its previous model of open-ended investing to a traditional fixed-term venture capital fund. The money will be dedicated to spinouts from Cambridge University, with CIC investing in series A rounds, but also following on as companies mature and their capital requirements increase. Read More
Blackrock Neurotech LLC has acquired spatial computing software startup Mindx Corp. to advance full-stack brain-computer interface (BCI) products. As part of the transaction, Mindx’s augmented reality (AR) and artificial intelligence (AI) technology will be integrated with Blackrock’s BCI hardware. Read More
Nanobiotix SA has just presented new data from an open-label preclinical study evaluating the action of its nanoparticle-enhanced radiotherapy, NBTXR3, with the triple blockade of PD-1, LAG-3, and TIGIT on mice carrying cancerous cells. PD-1, LAG-3 and TIGIT are three checkpoint inhibitors which regulate the natural killer cells usually targeted in combination therapy in immuno-oncology. Read More
A new animal model of systemic lupus erythematosus (lupus) could be useful for understanding the disparity of the disorder, which is vastly more common in women than men. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: AMP, Agnes Medical, ASCO, Carestream, Cerus, Hologic, Nido, Philips, Thermo Fisher. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Conextions. Read More
